TIGIT-targeted IL-12 fusion protein engages NK and CD8+ T cells for potent tumor immunotherapy - PubMed
5 hours ago
- #IL-12 fusion
- #cancer immunotherapy
- #TIGIT targeting
- A fusion protein named αTIGIT-IL12 (T-12) was developed to overcome the systemic toxicity limitations of wild-type IL-12 by fusing an anti-TIGIT scFv with IL-12.
- T-12 selectively targets tumor sites, activating intratumoral NK and CD8+ T cells, leading to potent anti-tumor effects in various mouse models, including checkpoint-insensitive and metastatic tumors.
- Compared to wild-type IL-12, T-12 shows improved safety with up to a 100-fold higher maximum tolerated dose and preferentially activates tumor-infiltrating immune cells over peripheral ones.